Navigation Links
Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting
Date:9/21/2010

DANBURY, Conn., Sept. 21 /PRNewswire/ -- In a platform presentation at the 46th annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, investigators for Biodel Inc. (Nasdaq: BIOD) today presented the results of a clinical study evaluating a new pH-neutral formulation of Linjeta™ (VIAject®).   Dr. Tim Heise (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues reported that the new pH-neutral, 100 IU/ml formulation of Linjeta™ was bioequivalent to the previously studied pH-4, 25 IU/ml formulation of Linjeta™, and had faster absorption and onset of action than insulin lispro.  These findings were also presented by Dr. Heise in June at the 70th scientific sessions of the American Diabetes Association in Orlando, Florida.

Linjeta™ is Biodel's more-ultra-rapid-acting insulin formulation that is currently under review by the U.S. Food and Drug Administration.  The purpose of this study was to demonstrate the bioequivalence of the two formulations of Linjeta™, compare the pharmacokinetic and pharmacodynamic characteristics of pH-neutral, 100 IU/ml Linjeta™ and insulin lispro in 43 patients with Type 1 diabetes.  The trial was conducted as a randomized, double-blind crossover study.  There were no serious adverse events or discontinuations because of treatment-emergent adverse events; headache was the most frequent adverse event reported (8 patients).  Additional studies are planned to evaluate the impact of Linjeta™ on glucose control.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs.  Biodel's new d
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
2. Dynatronics to Release Fourth Quarter and Year-End Results Wednesday, September 22, 2010; Conference Call Set for 1:00 p.m. ET
3. LightPath Technologies Announces Fourth Quarter and Fiscal 2010 Financial Results
4. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
5. Corgenix to Host Conference Call to Discuss Fiscal 2010 Results
6. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
7. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
8. Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Streamline Health® Solutions Reports Q2 Results
11. ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmins Potential to Transform the Treatment of Retinal Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Medical Equipment Solutions, ... been awarded a Department of Defense (US Army) contract ... supply a mobile MRI diagnostic machine and technical support ... (WOSB) through the Small Business Administration (SBA), Medical Equipment ... field with the latest medical diagnostic equipment. The SBA ...
(Date:7/30/2014)... SUNNYVALE, California , July 30, 2014 /PRNewswire/ ... GPU technology and CUDA programming expertise to big ... other markets  eInfochips, a leading engineering ... to clients to develop NVIDIA GPU-powered solutions for ... , high-performance computing (HPC), industrial ...
(Date:7/29/2014)... 29, 2014 Amgen (NASDAQ: AMGN ... of 2014. Key results include: , Total revenues ... product sales growth driven by strong performance across the ... (carfilzomib), Prolia ® (denosumab) and XGEVA ® ... $2.37, driven by higher revenues and a significant increase ...
Breaking Medicine Technology:Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... , , FREMONT, Calif., Nov. 24 ... its Plan of Reorganization and Disclosure Statement today, November 24, ... of Delaware. A hearing to consider approval of the Disclosure ... hearing on the confirmation of the Plan scheduled for January ...
... , ... developer and marketer of the VerifyNow® System, the first rapid ... multiple antiplatelet agents (e.g. Plavix® and aspirin), announced today that ... J. Tibbitts, Chief Financial Officer of Accumetrics, will be presenting ...
Cached Medicine Technology:Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... New York (PRWEB) July 30, 2014 ... uncontrollable brain bleeding has filed a Xarelto lawsuit ( ... the blood thinner, Bernstein Liebhard LLP reports. According to ... for the District of Vermont on July 25th, the ... when he suffered an irreversible brain bleed that ultimately ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... just received a major grant from the National Center ... the National Institutes of Health (NIH) and lead Federal ... new grant creates a Center of Excellence for Research ... will focus on Alzheimers disease. The new Center has ...
... 2007. A report to be published in an upcoming ... for urgent attention to the politically sensitive issue of border ... in the face of a catastrophic flu pandemic . ... of a strain of avian influenza A (HN51) in Northern ...
... today,announced it received a $250,000 grant from the ... support services. The university will use the ... professions. The newly created program, named the ... help the university recruit and support,Hispanic women in ...
... for Eating Disorders Reports Eating Disorders Develop or ... Worsen Upon Returning ... Eating Disorders, http://www.remudaranch.com, the nation,s leading eating disorder treatment,center, ... A majority of eating disorders begin at ages 14 and ...
... Governor,Arnold Schwarzenegger held a press conference announcing ... state legislature aimed at producing,reforms to California,s ... Policies Institute issued the following statement:, ... solve California,s,health care crisis," said Jill Jenkins, ...
... YORK, Oct. 10 Philip K. Howard, Chair of Common,Good, ... in response to a recent study on health courts that ... "The American Association of Justice (formerly known as the Association ... a study that it commissioned on the ...
Cached Medicine News:Health News:Mount Sinai recognized as Center of Excellence for Research in Alzheimer's disease 2Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 3Health News:Going Back to School Can Trigger Eating Disorders 2Health News:Going Back to School Can Trigger Eating Disorders 3Health News:Common Good Responds to a Trial Bar Study Opposing Health Courts 2
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
Intended for the quantitative determination of creatinine in serum, plasma, or urine. Reaction: Endpoint. Wavelength: 340 nm. Linearity: 10 mg/dL (880 mol/L). Two vials, dry powder reagents....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
Medicine Products: